Emerg Infect Dis by Whittemore, Kate et al.
misidentified as C. haemulonii, C. famata, C. albicans, or 
C. tropicalis, depending on the method used in the hospital. 
The identification of isolates by MALDI-TOF mass spec-
trometry has also been described in the literature as an ad-
equate and fast method for identifying C. auris (7).
Because the Clinical and Laboratory Standards Insti-
tute does not currently provide breakpoints for C. auris, no 
categorical interpretation of results is available; thus, only 
the MICs obtained for antifungal drugs tested in our study 
were indicated (Table). Although misleading, elevated 
MICs of amphotericin B by VITEK card have been pre-
viously described (7); this study also found discrepancies 
with Etest strips, which could lead to the selection of inap-
propriate therapy if only 1 method is used.
The presence of C. auris in these patients has clini-
cal and epidemiologic implications, considering the asso-
ciated mortality rate confirmed in this report and the ab-
sence of sufficient technology in clinical laboratories both 
to confirm their identification and to carry out testing for 
antifungal susceptibility. The lack of suitable diagnostics 
complicates patient treatment and changes on the empiric 
treatment of invasive Candida spp. infections are needed.
Our data contributes to the knowledge of the epidemi-
ology of this species at a regional level. Although we had 
already reported Candida spp. in Colombia (8), no informa-
tion regarding these species on the Caribbean coast is avail-
able. Given the association of Candida spp. with outbreaks 
in hospitals, according to the Centers for Disease Control 
and Prevention, it is necessary to further strengthen mea-
sures for fungal infection control to prevent possible spread.
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We surveyed women in New York, New York, USA, who 
were in areas with active Zika virus transmission while 
pregnant. Of 99 women who were US residents, 30 were 
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unaware of the government travel advisory to areas with 
active Zika virus transmission while pregnant, and 37 were 
unaware of their pregnancies during travel. 
Zika virus is primarily transmitted by the bite of infected Aedes mosquitoes; the virus can also cross the placenta 
of infected pregnant women, potentially leading to congen-
ital infection and serious birth defects (1–3). As of October 
7, 2016, a total of 617 cases of Zika virus infection had 
been identified among New York City (NYC) residents, in-
cluding 72 cases among pregnant women (4).
Despite government advisories in place since early 2016 
recommending that pregnant women avoid travel to areas with 
active Zika virus transmission (4,5), the NYC Department of 
Health and Mental Hygiene (DOHMH) saw an increase in 
weekly Zika virus test requests through the summer for wom-
en who had been in such areas while pregnant. This increase 
alerted the DOHMH to the need for additional messaging. To 
guide this communication, we conducted telephone surveys to 
evaluate Zika virus knowledge and practices among women in 
NYC who had been in such areas while pregnant.
In brief, during June 1–July 15, 2016, the DOHMH 
Zika Testing Call Center facilitated testing for 1,086 wom-
en >18 years of age because they were pregnant while in an 
area with active Zika virus transmission (6) (online Techni-
cal Appendix, https://wwwnc.cdc.gov/EID/article/23/1/16-
1614-Techapp1.pdf). At the time of receiving the Zika virus 
test request, DOHMH collected demographic data, contact 
information and other pertinent clinical history on the pa-
tients; these 1,086 women were potentially eligible for the 
survey if their telephone number had been provided. The 
women were called in random order until ≈100 provided 
consent and completed the survey. Descriptive statistics 
were calculated for responses to each survey question. 
After 642 eligible women had been called, the target 
number of respondents had provided consent and completed 
the survey (n = 121; 18.8%); 67 (55.4%) respondents were 
interviewed in Spanish. We found no statistically significant 
differences in demographic characteristics between respon-
dents and nonrespondents (online Technical Appendix Table).
Of the 121 respondents, 99 (81.8%) were US residents 
(considered the United States their home). Approximately 
one third of the US residents (n = 30; 30.6%) were unaware 
of the government advisory (recommending that pregnant 
women avoid travel to areas with active Zika virus trans-
mission) at the time of travel (Table). Nearly half (n = 43; 
44.3%) did not know that there was active Zika virus trans-
mission in areas where they traveled, and more than one 
third (n = 37; 38.5%) did not know that they were pregnant 
during travel. Of the 30 US residents who were aware of 
the government advisory, were aware of active Zika virus 
transmission in areas where they traveled, and knew that 
they were pregnant during travel, 7 (23.3%) still traveled 
because their trips were too expensive to cancel. Of 6 US 
residents who did not know about the government advi-
sory but did know of active Zika virus transmission in areas 
where they traveled and did know that they were pregnant 
during travel, 5 (83.3%) said they would not have traveled 
had they known about the government advisory. The most 
frequently reported reason for travel among US residents 
was to visit friends or relatives (n = 68; 70.1%). 
Among the women we surveyed, many were unaware 
of the government travel advisory, unaware of active Zika 
virus transmission in areas where they traveled, or unaware 
of their pregnancy during travel. However, our survey had 
limitations. The small sample size limited our ability to 
perform sophisticated analyses, and the potential for social 
desirability and recall bias are inherent to the study design. 
The survey questionnaire was not a validated instrument. 
Also, the women described here completed the survey after 
Zika virus testing; therefore, it is possible that they had a 
better understanding than the general public. 
Most participants in our survey were interviewed in 
Spanish. This finding underscores the need for providing 
educational materials in multiple languages. 
Although our findings cannot be generalized, they pro-
vide insight for increased and improved public health mes-
saging. Public health authorities in the United States should 
continue to raise awareness among women of reproduc-
tive age about the risk for Zika virus infection from travel, 





Table. Knowledge about Zika virus infection among US residents who were pregnant at time of travel to areas with active Zika virus 
transmission, New York, NY, USA, June 1–July 15, 2016* 
Characteristic Total responses Yes (%)* No (%)* 
Aware of government travel advisory at time of travel to areas with active Zika virus 
transmission 
98 68 (69.4) 30 (30.6) 
Aware that areas of travel had active Zika virus transmission 97 54 (55.7) 43 (44.3) 
Aware of pregnancy status at time of travel to areas with active Zika virus transmission 96 59 (61.5) 37 (38.5) 
Reason for travel     
  Visiting friends or relatives 97 68 (70.1) 29 (29.9) 
  Tourism 97 52 (53.6) 45 (46.4) 
  Other 87 24 (27.6) 63 (72.4) 
  Business 97 5 (5.1) 92 (94.9) 
  Education 97 5 (5.1) 92 (94.9) 
  Service-related 97 4 (4.1) 93 (95.9) 
*Column percentages do not total 100% because categories are not mutually exclusive. Denominator includes only those respondents who answered the 
question. 
 
enabling them to better make informed decisions. Women 
who are trying to become pregnant or who are pregnant 
should avoid travel to areas with active Zika virus transmis-
sion and, if they must travel, should talk to their healthcare 
provider first and take steps to minimize exposure to Zika 
virus. Furthermore, women who are trying to become preg-
nant should follow Centers for Disease Control and Preven-
tion (Atlanta, GA, USA) guidelines on how long to wait 
to get pregnant after a potential Zika virus exposure (7). 
Women who want to avoid pregnancy and their male part-
ners should use effective birth control correctly and consis-
tently (8). Healthcare providers in the United States caring 
for pregnant women and women who are trying to become 
pregnant should routinely discuss travel history and travel 
plans with their patients.
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Since 2013, wounded and ill children from Syria have re-
ceived treatment in Israel. Screening cultures indicated that 
multidrug-resistant (MDR) pathogens colonized 89 (83%) 
of 107 children. For 58% of MDR infections, the pathogen 
was similar to that identified during screening. MDR screen-
ing of these children is valuable for purposes of isolation 
and treatment.
As the civil war in Syria enters its sixth year, the United Nations estimates that ≈250,000 persons have been 
killed, ≈10,000 of them children (1). Preliminary reports 
indicate a high rate of multidrug-resistant (MDR) pathogen 
carriage among refugees from Syria, mostly adults (2–5). 
Preliminary data for 29 wounded Syrian children indicate 
that 66% carried extended-spectrum β-lactamase–produc-
ing Enterobacteriaceae (ESBL) (2).
For ≈3 years, Syrian children who were ill or severely 
wounded from the civil war have been secretly transported 
across the border for treatment in Israel, mainly at Galilee 
Medical Center (GMC; Nahariya, Israel). We characterized 
carriage of and infections with MDR pathogens among 
these children.
We prospectively collected demographic and clini-
cal microbiology data for all Syrian children 0–17 
years of age who were admitted to GMC during March 
2013–February 2016. At admission, contact isolation 
and screening cultures for MDR were conducted. MDR 
pathogens belonged to 1 of 5 groups: ESBL, carbapen-
em-resistant Enterobacteriaceae (CRE), methicillin-
resistant Staphylococcus aureus, MDR Acinetobacter 
baumannii (MDR-AB), and vancomycin-resistant En-
terococcus. Culture sites included nares, axilla, groin, 
rectum, and open wounds. Bacterial identification and 
susceptibility testing were performed according to 
Clinical and Laboratory Standards Institute guidelines 
(http://clsi.org/standards/micro/). For CRE screening, 
we used CHROMagar plates (hylabs, Rehovot, Israel). 
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